Sensipar — CareFirst (Caremark)
Secondary hyperparathyroidism in adult patients with chronic kidney disease on dialysis
Initial criteria
- Member has chronic kidney disease on dialysis
- Serum calcium level (corrected for albumin) ≥ 8.4 mg/dL
Reauthorization criteria
- Member is experiencing benefit from therapy as evidenced by a decrease in intact parathyroid hormone (iPTH) levels from pretreatment baseline
Approval duration
12 months